Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBP 501

Drug Profile

CBP 501

Alternative Names: CBP-501; Cdc25C phosphatase (211-221)

Latest Information Update: 28 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CanBas
  • Class Antineoplastics; Peptides
  • Mechanism of Action 14-3-3 protein inhibitors; Calmodulin antagonists; Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)
  • 29 Mar 2019 Efficacy data and adverse events from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 20 Sep 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03113188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top